A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2018
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; MP 0250 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Molecular Partners AG
- 30 Aug 2018 According to a Molecular Partners media release, the company anticipates additional safety data and initial efficacy data to be disclosed before year-end 2018.
- 29 Jun 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2019.
- 29 Jun 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History